U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne

NCT01706263 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Acne Vulgaris

Interventions

DRUG: MAXCLARITY II (2.5% BPO) Foam Cleanser
DRUG: MAXCLARITY II (2.5% BPO) Foam Treatment
DRUG: MAXCLARITY II (0.5% Salicylic Acid) Toner Foam

Sponsor

Stiefel, a GSK Company

Collaborators

[object Object]